key: cord-0972065-ukyc8sch authors: Ghia, Samit; Bhatt, Himani; Lazar, Michael title: Role of Tissue Plasminogen Activator for Diffuse Pulmonary Micro Emboli in COVID-19 Patient date: 2020-08-31 journal: J Cardiothorac Vasc Anesth DOI: 10.1053/j.jvca.2020.08.063 sha: a8895377facd092884ced4803349f93df19f2ebe doc_id: 972065 cord_uid: ukyc8sch SARS-CoV2 related hypercoagulability has been of great interest in the pathophysiology of coronavirus disease 2019 (COVID-19). Many patients have clinical findings of dead space ventilation, similar to pulmonary embolism (PE). We describe a patient who presented with COVID-19 pneumonia who rapidly deteriorated to respiratory failure requiring intubation. Tissue plasminogen activator (tPA) was administered due to concern of pulmonary micro emboli with improvement of respiratory status and extubation within 24 hours. Patients with COVID-19 infections have an increased risk of thrombus formation(1) and the administration of tPA may benefit these patients by immediately lysing diffuse thrombi and improve gas exchange. Since its origination in Wuhan, China, COVID-19, which is caused by the severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) virus, has rapidly spread leading to a worldwide pandemic. There has been a growing interest in the role of hypercoagulability that has been demonstrated in COVID patients with many often presenting with diffuse thrombosis 2 . Some of the thrombotic disease has manifested as widespread micro emboli with a large clot burden leading to the morbidity and mortality seen with this disease. Appropriate anticoagulation therapy has become the subject of much discussion and multiple hospitals have put forth institutional policies to address the initiation of anticoagulation in moderate to severe disease. However, it is unclear how many patients rapidly develop diffuse thrombus formation and what the optimal timing of therapy is. Thrombolytic therapy, i.e. tPA, may have a role in treating these patients, and may prevent further deterioration secondary to large clot burden. This manuscript adheres to the applicable EQUATOR guideline. The appropriate HIPAA authorization was obtained from the patient's healthcare proxy for the submission of this report. An 81-year-old male with a history of hypertension, hyperlipidemia, gastric ulcer, aortic valve replacement, and chronic lymphocytic leukemia presented to the emergency room (ER) complaining of fever and cough for 10 days and new onset shortness of breath with chest pain for 24 hours. He had a mild lymphocytosis, elevated inflammatory markers (i.e. ferritin, Creactive protein, lactate dehydrogenase, d-dimer, and procalcitonin), and bilateral opacities on chest radiograph. The patient was admitted with viral pneumonia due to moderate/severe COVID-19 1 . He was started on hydroxychloroquine, azithromycin and broad-spectrum antibiotics. While in the ER his oxygenation worsened on non-rebreather (NRB), he was transitioned to bilevel positive airway pressure (bipap) and screened into the intensive care unit (ICU). On admission to the ICU, methylprednisolone, aspirin, and subcutaneous heparin were added to his medication regimen. Due to frequent episodes of supraventricular tachycardia and atrial fibrillation, he was started on apixaban 5 mg daily per cardiology recommendation. His QTc rose to 538 and so the hydroxychloroquine was discontinued. Additionally, the patient began self-proning daily for 8 hour shifts with no appreciable improvement. On admission day 6, the patient received as dose of tocilizumab for an elevated interleukin-6 level and therapeutic enoxaparin was started in place of apixaban due to concern for insufficient anticoagulation. However, he continued to decompensate with persistent hypoxia (partial pressure of arterial oxygen (PaO 2 ) of 43 mmHg on 100% fraction of inspired oxygen (FiO 2 ) on bipap), worsening respiratory distress and was intubated on day 7. After intubation, his oxygenation initially improved on ventilator settings with tidal volumes of 400 mL, respiratory rates of 22, positive end expiratory pressure (PEEP) of 12, and FiO2 of 100%. However, dead space ventilation was apparent with a persistent hypercarbia and alveolar pressures of 12-15 mmHg. Due to recent respiratory deterioration and suspicion for diffuse pulmonary microthrombi, tPA was administered without further workup or diagnostic studies. The dose administered was a 6 mg bolus and 2 mg per hour infusion over 22 hours. During the thrombolytic infusion, the P/F (PaO 2 /FiO 2 ) ratio improved to 142 (PaO2 of 114 mmHg on a FiO2 of 80%) on day 8. After completion of the tPA infusion the patient was started on a heparin infusion. By day 9, his ventilator was weaned to a FiO2 of 40%, he tolerated a spontaneous breathing trial and was extubated to bipap at 40%. Arterial blood gas showed resolution of the dead space ventilation (partial pressure of arterial carbon dioxide (PaCO 2 ) of 30.5 mmHg) and his P/F ratio drastically increased to 610 (PaO2 of 244 mmHg on a FiO2 of 40%). Table 1 summarizes pulmonary and arterial gas measurements around the time of tPA administration. D-dimers, elevated at 2.8 upon presentation, increased to 16.91 after initiation of tPA before trending downwards. However, the lytic and anticoagulation treatment was complicated by melena consistent with an upper gastrointestinal bleed. After discontinuation of heparin and aspirin, 2 units of packed red blood cells were given to treat an acute blood loss anemia. He transitioned to NRB over the next few days, was transferred out of the ICU on day 13 and discharged on day 28. In COVID-19, caused by SARSCoV-2, injury to the alveoli is thought to be the major cause of hypoxia and acute respiratory distress syndrome (ARDS) 3 . Hypercoagulation appears to also be involved in the disease process, not merely sepsis related disseminated intravascular coagulation. Coagulation markers, including D-dimer and fibrinogen, have been elevated in patients with COVID-19. Implementation of anticoagulation has decreased morbidity and mortality 2 and autopsies have found diffuse alveolar damage and microvascular thrombi in the lungs 4 . The exact mechanism of hypercoagulability is not yet understood. One postulation points to the functional receptor of the virus. ACE2 is a counter regulatory component of the renin angiotensin system. Angiotensin II, which is cleaved by ACE2, is pro-inflammatory, prothrombotic, and vasoconstrictive. ACE2 protects against excessive angiotensin II and some animal models showed COVID-19 was associated with a downregulation of the enzyme 5 . PE, as well as diffuse pulmonary micro emboli, causes dead space ventilation by impairing appropriate alveolar perfusion. The findings seen in our case were hypoxia, persistent hypercarbia in high minute ventilation, and normal lung compliance. Although he was on systemic anticoagulation, it possibly had limited efficacy due to the high clot burden theorized in patients with moderate/severe COVID-19. In these cases, while there are no prospective studies evaluating the efficacy of tPA in COVID-19 due to its novelty, we hypothesize thrombolytic therapy dissolves current micro emboli while subsequent anticoagulant prevents re-clotting, improves gas exchange, lung perfusion, and oxygenation. Lung compliance in ARDS worsens as the severity increases. As the lung injury worsens leading to more edema, lung weight, and atelectasis, the volume of air in the lungs is displaced leading to dyspnea and hypoxia. However, many patients with severe COVID-19 pneumonia have severe hypoxia with normal lung compliance and poor responsiveness to increasing levels of PEEP. These patients, much like the patient in this case, have pulmonary physiology more like dead space ventilation than shunting, suggestive of PE or pulmonary micro emboli. As they remain on the ventilator longer, some patients progress to a more traditional ARDS. In our case, there was a significant clinical improvement possibly because the disease had not progressed to advanced stages. He was the only patient in our unit who was intubated for less than 72 hours. With the development of alveolar injury and pulmonary fibrosis, impaired gas exchange may be irreversible. Wang et al discussed three cases where tPA transiently improved P/F ratios, but had little effect on their clinical condition. Important to note, all three patients were intubated and on vasopressor support alluding to late stages of COVID-19 6 . We credit the improvement in our patient to tPA because he continued to deteriorate while receiving other anticoagulants. We postulate anticoagulants such as heparin or apixaban were ineffective because they block clot formation but do not induce clot breakdown 7 . However, we must acknowledge that he was on concomitant anticoagulants that may have affected his hospital course. When considering tPA, risks and benefits must be appreciated. The benefits have been noted in approved indications such as pulmonary embolism, ischemic stroke and ST elevation myocardial infarction. Nonetheless, sometimes the risk outweighs the benefit in contraindicated states such as signs and symptoms of active bleeding 8 . Bleeding or hemorrhage is a serious risk of thrombolytic therapy, as was seen in our case, and coagulation studies can guide its titration 9 . Further investigation will help shed light on the legitimacy of thrombolytic therapy and its ideal timing, dosing, and criteria for inclusion. COVID-19 pathophysiology: A review Thromboinflammation and the hypercoagulability of COVID-19 Pathogenesis of COVID-19 from a cell biology perspective Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19 Tissue Plasminogen Activator (tPA) Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Case Series Anticoagulation drug therapy: a review StatPearls [Internet Is There a Role for Tissue Plasminogen Activator (tPA) as a Novel Treatment for Refractory COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS)